Encapharm RP18 is a reversed-phase HPLC column based on fully porous, high-purity silica and modified with octadecyl (C18) groups using advanced bonding and full endcapping technology. This phase delivers strong hydrophobic retention, excellent peak symmetry, and low silanol activity, making it ideal for the separation of basic, neutral, and moderately polar analytes in pharmaceutical and analytical workflows.
Encapharm RP18 ensures reliable results in both gradient and isocratic conditions, supporting high-efficiency and high-reproducibility reversed-phase chromatography.
Encapharm RP18 provides high-performance reversed-phase separation with full endcapping – ideal for demanding HPLC applications where peak quality and retention stability matter.
C18 (octadecyl) bonded phase – USP L1 classification
Fully endcapped to reduce peak tailing of basic compounds
Strong hydrophobic retention with excellent peak shape
Fully porous, high-purity silica for stable performance
Available in 3 µm and 5 µm particle sizes
API analysis and impurity profiling in pharmaceutical QC
Separation of basic and polar compounds
Method development and validation in regulated environments
Routine reversed-phase analysis requiring high reproducibility
| Particle Sizes |
|
|---|---|
| Pore Size | 130 Å |
| Surface Area | 250 m²/g |
| Phase/Modification | C18 |
| Particle Type | |
| Separation Mode | |
| USP Code | |
| Endcapping | Yes |
| Carbonload | 22 % |
| Phase | Material Number |
|---|---|
| Encapharm RP18, 3 µm | en13.9e. |
| Encapharm RP18, 5 µm | en15.9e. |